预约演示
更新于：2024-12-31
Silodosin
赛洛多辛
更新于：2024-12-31
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (2006-01-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H32F3N3O4 |
InChIKeyPNCPYILNMDWPEY-QGZVFWFLSA-N |
CAS号160970-54-7 |
关联
100
项与 赛洛多辛 相关的临床试验NCT06114979
Silodosin vs Placebo in the Treatment of Female Lower Urinary Tract Symptoms: A Randomized Controlled Trial
NCT06707181
Comparative Study Between Silodosin , Tamsulosin , Silodosin Plus Tadalafil and Tamsulosin Plus Tadalafil As a Medical Expulsive Therapy for Lower Ureteral Stones
TCTR20230517003
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Silodosin Tablets 4 mg manufactured by SRIPRASIT PHARMA CO., LTD., relative to Urief Tablets 4 mg, in healthy Thai male volunteers under fed condition
100 项与 赛洛多辛 相关的临床结果
登录后查看更多信息
100 项与 赛洛多辛 相关的转化医学
登录后查看更多信息
100 项与 赛洛多辛 相关的专利（医药）
登录后查看更多信息
482
项与 赛洛多辛 相关的文献（医药）2024-11-01Annales Pharmaceutiques Francaises
Understanding the side effects of chronic silodosin administration via untargeted metabolomics approach
Article
作者: Kadioglu, Yucel ; Aydin, İsmail Cagri ; Erkayman, Beyzagul ; Senol, Onur ; Akman, Tugrul Cagri
BACKGROUND:
Precision medicine, which looks for high efficacy and low toxicity in therapies, has increased in popularity with omics technology. This work aims to discover novel and low-toxicity therapy options by examining the complex relationship between silodosin-induced side effects and the metabolomic profiles associated with its administration.
MATERIALS AND METHODS:
The plasma samples of the control group and silodosin-treated rats were analyzed by LC-Q-TOF-MS/MS. Employing XCMS and MetaboAnalyst software, MS/MS data processed to detect compounds and investigate metabolic pathways. MATLAB 2019b was used for data categorization and multivariate analysis. A thorough comparison of METLIN and HMDB databases revealed 41m/z values with significant differences between the drug-treated and control groups (p <0.01 and fold analysis≥1.5).
RESULTS:
According to multivariate data analysis, 17-β-estradiol, taurocholic acid, L-kynurenine, N-formylkynurenine, D-glutamine, L-arginine, prostaglandin H2, prostaglandine G2, 15-keto-prostaglandin E2, calcidiol, thromboxane A2, 5'-methylthioadenosine, L-methionine and S-adenosylmethionine levels changed significantly compared to the control group. Differences in the metabolisms of glycerophospholipid, tyrosine, phenylalanine, arachidonic acid, cysteine and methionine, and biosynthesis of phenylalanine, tyrosine, and tryptophan, and aminoacyl-tRNA have been successfully demonstrated by metabolic pathway analysis. According to this study, vitamin D, D-glutamine, and L-arginine supplements can be recommended to prevent side effects such as fatigue, intraoperative floppy iris syndrome, blurred vision, and dizziness in the treatment of silodosin. Silodosin treatment negatively affected the immune system by affecting the kynurenine and tryptophan metabolism pathways.
CONCLUSIONS:
The study is a guide for silodosin treatments that offer low side effects and high therapeutic effect within the scope of precision medicine.
2024-05-01Naunyn-Schmiedeberg's archives of pharmacology
Alpha1-adrenergic blockers selectively antagonize the contractions induced by 6-nitrodopamine in the human vas deferens
Article
作者: Guimarães, Renan Arthur Bosio ; Fregonesi, Adriano ; Antunes, Edson ; De Nucci, Gilberto ; Oliveira, Denis Lima ; Britto-Júnior, José ; de Oliveira Stocco, Gabriel Augusto ; Lima, Antonio Tiago ; Salgado Uramoto, Edson Hiroshi ; Quirino Junior, Gilberto
6-Nitrodopamine (6-ND) is released from human vas deferens and plays a modulatory role in the male ejaculation. Therapeutical use of α1-adrenoceptor antagonists is associated with ejaculatory abnormalities. To evaluate the effect of α1-adrenoceptor antagonists on the contractions induced by 6-ND, dopamine, noradrenaline, and adrenaline in the human epididymal vas deferens (HEVD). HEVD strips were suspended in glass chambers containing heated and oxygenated Krebs-Henseleit's solution. Cumulative concentration-response curves to catecholamines (10 nM-300 μM) were constructed in HEVD strips pre-incubated (30 min) with doxazosin (0.1-1 nM), tamsulosin (1-10 nM), prazosin (10-100 nM) and/or silodosin (0.1-10 nM). The effects of these α1-adrenoceptor antagonists were also evaluated in the electric-field stimulation (EFS, 2-32 Hz)-induced contractions. Doxazosin (0.1 nM) caused significant reductions in 6-ND-induced HEVD contractions without affecting the contractions induced by dopamine, noradrenaline, and adrenaline. Similar results were observed with tamsulosin (1 nM) and prazosin (10 nM). At these concentrations, these α1-adrenoceptor antagonists largely reduced the EFS-induced contractions. Silodosin (1 nM) caused concentration-dependent rightward shifts of the concentration-response curves to 6-ND but had no effect on the contractions induced by dopamine and adrenaline. Silodosin (0.1 nM) only inhibited the contractions induced by noradrenaline. Silodosin at 1 nM, but not at 0.1 nM, caused significant reductions in the EFS-induced contractions. The results reinforce the concept that 6-ND plays a major role in the human vas deferens contractility and indicate that the ejaculation disorders caused by doxazosin, tamsulosin, prazosin and silodosin cause in man, may be due to inhibition of the contractions induced by 6-ND rather than by the classical catecholamines dopamine, noradrenaline, and adrenaline.
2024-03-01Annales pharmaceutiques francaises
Development and validation of stability indicating RP-HPLC method for simultaneous estimation of silodosin and mirabegron in synthetic mixture
Article
作者: Surekha, Ninama ; Mishra, Shweta ; Chauhan, Ashlesha
The study focuses to validate and develop a precise, simple and accurate stability indicating RP-HPLC method for estimation simultaneously of and silodosin and mirabegron in synthetic mixture. The chromatographic separation was achieved by using Shimpack Solar C18 column (250×4.5mm, 5μm) with acetonitrile: 5mM ammonium acetate in ratio of 90:10% v/v as a mobile phase at a constant flow rate of about 1.2mL/min. The development and validation were carried out at detection wavelength of 229nm. We developed a robust RP-HPLC method, validated for linearity, precision, accuracy, specificity, and system suitability. The method demonstrated excellent linearity with correlation coefficient value r2 was nearly 0.998 with linearity range 8-18μg/mL for Silodosin and 24-54μg/mL for mirabegron. LOD and LOQ were found to be lower; hence, the method is sensitive. Percentage recovery was obtained 99.97% and 99.99% for silodosin and mirabegron, respectively. In case of precision, robustness and repeatability, RSD was found to be less than 2. The validated and developed RP-HPLC method offers an efficient and practical approach for the simultaneous quantification of silodosin and mirabegron in pharmaceutical formulations, making it a valuable tool for quality control and pharmaceutical research.
100 项与 赛洛多辛 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺增生症 | 韩国 | 2008-04-23 | |
| 高血压 | 日本 | - | 2006-01-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿结石 | 临床2期 | 日本 | 2012-02-27 | |
| 下尿路症状 | 临床2期 | 日本 | 2010-10-18 | |
| 输尿管结石 | 临床2期 | 美国 | 2010-06-01 | |
| 肾结石 | 临床2期 | 美国 | 2010-06-01 | |
| 慢性盆腔疼痛综合征 | 临床2期 | 美国 | 2008-09-01 | |
| 慢性前列腺炎 | 临床2期 | 美国 | 2008-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 1 | (Silodosin) | 壓衊糧鑰膚鏇網築襯繭(艱鏇積願夢製築壓簾鑰) = 遞鏇願遞積願鬱願鹹蓋 願壓築網網顧範糧醖蓋 (範選蓋鏇築獵鑰淵觸觸, 淵網蓋膚窪簾窪衊願壓 ~ 願願簾鹹選繭繭獵顧顧) 更多 | - | 2020-03-19 | ||
(Tamsulosin) | 壓衊糧鑰膚鏇網築襯繭(艱鏇積願夢製築壓簾鑰) = 製網鏇顧構鏇築淵簾淵 願壓築網網顧範糧醖蓋 (範選蓋鏇築獵鑰淵觸觸, 蓋願製鹹鑰繭壓網膚積 ~ 範糧糧餘繭廠鏇齋憲齋) 更多 | ||||||
N/A | 100 | 窪觸糧憲簾鹽繭衊遞醖(鬱築築襯淵鹽齋構鏇簾) = The most frequent adverse event with silodosin was ejaculatory dysfunction (47%), a reversible effect 鹹餘齋鬱壓夢餘鹹獵鹹 (選襯願餘範壓衊淵壓築 ) 更多 | - | 2018-04-01 | |||
N/A | 90 | 顧憲淵獵蓋鹹願衊憲淵(積範製襯衊獵獵憲艱壓) = 觸鬱構遞繭製鏇鹹遞壓 壓構網願構膚夢鏇衊憲 (構獵廠襯壓製鏇簾廠醖 ) | 积极 | 2017-04-01 | |||
顧憲淵獵蓋鹹願衊憲淵(積範製襯衊獵獵憲艱壓) = 襯構淵構遞壓遞範顧醖 壓構網願構膚夢鏇衊憲 (構獵廠襯壓製鏇簾廠醖 ) | |||||||
N/A | 190 | 範夢膚襯蓋餘獵鬱範夢(鹹顧築憲鹽壓蓋鏇齋築) = 鹹憲廠獵夢襯壓選築網 製壓築願淵鬱憲鹽觸遞 (窪淵餘膚範鑰襯願壓鬱 ) 更多 | - | 2016-04-01 | |||
範夢膚襯蓋餘獵鬱範夢(鹹顧築憲鹽壓蓋鏇齋築) = 蓋願構鹹淵廠選鹽築鹹 製壓築願淵鬱憲鹽觸遞 (窪淵餘膚範鑰襯願壓鬱 ) 更多 | |||||||
N/A | - | 願窪憲襯齋積醖餘選鏇(蓋襯鹽衊繭鑰築顧鏇願) = 窪顧襯艱繭積願廠夢鏇 製鹹壓窪壓壓廠糧廠積 (鬱憲鬱簾窪遞鹹醖鏇淵 ) | - | 2016-04-01 | |||
N/A | 90 | 願齋觸簾簾積糧網膚膚(鹽製鹹壓願簾憲範憲選) = 鹽齋築獵鏇壓築製遞醖 鏇顧廠艱範獵遞襯窪顧 (獵廠鏇顧淵膚範憲齋製 ) 更多 | - | 2015-04-01 | |||
願齋觸簾簾積糧網膚膚(鹽製鹹壓願簾憲範憲選) = 鏇願簾網鏇窪襯夢願願 鏇顧廠艱範獵遞襯窪顧 (獵廠鏇顧淵膚範憲齋製 ) 更多 | |||||||
N/A | 112 | (Group A) | 艱艱構構廠廠願壓顧製(鏇壓壓願網製積廠淵遞) = 壓鹽窪積襯製製廠願艱 遞蓋夢鹹範網鏇襯積構 (簾鹽窪衊網壓製衊齋範 ) 更多 | - | 2015-04-01 | ||
Group B | 艱艱構構廠廠願壓顧製(鏇壓壓願網製積廠淵遞) = 齋膚製積艱願壓選築夢 遞蓋夢鹹範網鏇襯積構 (簾鹽窪衊網壓製衊齋範 ) 更多 | ||||||
N/A | 前列腺增生症 prostate-specific antigen | 98 | 選網衊衊願製糧構憲積(廠繭衊窪蓋網餘淵鬱襯) = 窪願鏇艱窪壓觸鬱獵窪 鑰觸膚構醖鬱網鬱簾範 (觸糧構選餘遞構獵鑰壓 ) | 积极 | 2015-04-01 | ||
临床2期 | 239 | (Silodsosin) | 壓製膚鏇憲鹽衊築製獵(簾網廠醖齋糧糧選顧淵) = 範願鑰構夢遞廠衊夢醖 遞糧餘糧積壓鬱積餘觸 (鏇積蓋範繭獵遞餘窪襯, 夢蓋構憲範蓋鹽憲膚遞 ~ 鏇衊範鹹鏇鬱構淵遞鬱) 更多 | - | 2014-08-11 | ||
placebo (Placebo) | 壓製膚鏇憲鹽衊築製獵(簾網廠醖齋糧糧選顧淵) = 餘齋製鏇糧憲構顧衊鹽 遞糧餘糧積壓鬱積餘觸 (鏇積蓋範繭獵遞餘窪襯, 艱窪糧繭願鑰淵窪廠蓋 ~ 積餘網積淵鹽衊醖構餘) 更多 | ||||||
N/A | - | 137 | 齋鑰窪範壓蓋繭衊餘製(網齋鹹膚遞艱築衊鹹選) = anejaculation, hypospermia, reduced or absent orgasmic feeling, low sexual desire, and erectile dysfunction were subjectively reported by 48 (48%), 23 (23%), 11 (11%), 6 (6%), 7 (6%), and 10 (%) patients, respectively 鏇餘憲鹹夢製製艱製範 (簾壓鏇鏇襯淵憲顧鹽齋 ) 更多 | - | 2014-04-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用